FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028160158> ?p ?o ?g. }

• W2028160158 endingPage "2102" @default.
• W2028160158 startingPage "2097" @default.
• W2028160158 abstract "SummaryMost tumors have constitutively active tissue factor on their surface, capable of generating thrombin in the surrounding environment, and thrombosis is associated with cancer. Thrombin is known to induce a malignant phenotype by enhancing tissue adhesion and cell growth in vitro and in vivo in mice. Because tumors require angiogenesis for growth, we examined whether thrombin induces neoangiogenesis in a physiologically intact in vivo model. Thrombin (0.1 U mL−1) induced neoangiogenesis in the chick chorioallantoic membrane over a 24–72-h period by approximately 2–3-fold. This was inhibited by the potent thrombin inhibitor, hirudin and shown to have its mode of action by ligation of the thrombin protease-activated receptor, PAR-1. The thrombin receptor activation peptide, SFLLRNPNDKYEPF (200 µm) also enhanced neoangiogenesis c. 2–3-fold. Thrombin-induced neoangiogenesis was accompanied by the induction of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) mRNA at 24–48 h (approximately 2-fold) as determined by semi-quantitative reverse transcriptase-polymerase chain reaction. Thrombin-induced neoangiogenesis was inhibited to baseline level by the specific angiogenesis receptor inhibitors KDR-Fc (vs. VEGF) and Tie-2-Fc (vs. Ang-1 and Ang-2), as well as the non-specific angiogenesis inhibitor thrombospondin-1. Thrombin-induced neoangiogenesis was also inhibited to baseline level by agents known to inhibit thrombin receptor signaling in other cells: G-coupled protein receptor inhibitor, pertussis toxin (40 pg per egg), protein kinase C inhibitor, bisindolylmaleimide (1 µm per egg), MAP kinase inhibitor, PD980598 (10 µm per egg) and PI3 kinase inhibitor, LY294002 (0.25 µm per egg). Thus angiogenesis is stimulated by thrombosis, which could help explain the enhancement of experimental tumorigenesis by thrombin. Most tumors have constitutively active tissue factor on their surface, capable of generating thrombin in the surrounding environment, and thrombosis is associated with cancer. Thrombin is known to induce a malignant phenotype by enhancing tissue adhesion and cell growth in vitro and in vivo in mice. Because tumors require angiogenesis for growth, we examined whether thrombin induces neoangiogenesis in a physiologically intact in vivo model. Thrombin (0.1 U mL−1) induced neoangiogenesis in the chick chorioallantoic membrane over a 24–72-h period by approximately 2–3-fold. This was inhibited by the potent thrombin inhibitor, hirudin and shown to have its mode of action by ligation of the thrombin protease-activated receptor, PAR-1. The thrombin receptor activation peptide, SFLLRNPNDKYEPF (200 µm) also enhanced neoangiogenesis c. 2–3-fold. Thrombin-induced neoangiogenesis was accompanied by the induction of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) mRNA at 24–48 h (approximately 2-fold) as determined by semi-quantitative reverse transcriptase-polymerase chain reaction. Thrombin-induced neoangiogenesis was inhibited to baseline level by the specific angiogenesis receptor inhibitors KDR-Fc (vs. VEGF) and Tie-2-Fc (vs. Ang-1 and Ang-2), as well as the non-specific angiogenesis inhibitor thrombospondin-1. Thrombin-induced neoangiogenesis was also inhibited to baseline level by agents known to inhibit thrombin receptor signaling in other cells: G-coupled protein receptor inhibitor, pertussis toxin (40 pg per egg), protein kinase C inhibitor, bisindolylmaleimide (1 µm per egg), MAP kinase inhibitor, PD980598 (10 µm per egg) and PI3 kinase inhibitor, LY294002 (0.25 µm per egg). Thus angiogenesis is stimulated by thrombosis, which could help explain the enhancement of experimental tumorigenesis by thrombin." @default.
• W2028160158 created "2016-06-24" @default.
• W2028160158 creator A5004781738 @default.
• W2028160158 creator A5065658935 @default.
• W2028160158 creator A5073325557 @default.
• W2028160158 creator A5074077148 @default.
• W2028160158 date "2003-10-01" @default.
• W2028160158 modified "2023-10-18" @default.
• W2028160158 title "Thrombin induces neoangiogenesis in the chick chorioallantoic membrane" @default.
• W2028160158 cites W1523242007 @default.
• W2028160158 cites W1596240955 @default.
• W2028160158 cites W177380973 @default.
• W2028160158 cites W1828447324 @default.
• W2028160158 cites W1970614272 @default.
• W2028160158 cites W1993401670 @default.
• W2028160158 cites W2000537146 @default.
• W2028160158 cites W2027525864 @default.
• W2028160158 cites W2029773366 @default.
• W2028160158 cites W2030729823 @default.
• W2028160158 cites W2036410266 @default.
• W2028160158 cites W2047408781 @default.
• W2028160158 cites W2055158504 @default.
• W2028160158 cites W2058468432 @default.
• W2028160158 cites W2066888615 @default.
• W2028160158 cites W2067817921 @default.
• W2028160158 cites W2084452119 @default.
• W2028160158 cites W2109339951 @default.
• W2028160158 cites W2121863324 @default.
• W2028160158 cites W2139776404 @default.
• W2028160158 cites W2152215024 @default.
• W2028160158 cites W2164654574 @default.
• W2028160158 cites W2165139012 @default.
• W2028160158 cites W2236085490 @default.
• W2028160158 cites W2273423172 @default.
• W2028160158 cites W2416635671 @default.
• W2028160158 cites W2461997793 @default.
• W2028160158 cites W3113181238 @default.
• W2028160158 cites W3113348859 @default.
• W2028160158 doi "https://doi.org/10.1046/j.1538-7836.2003.00426.x" @default.
• W2028160158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14521590" @default.
• W2028160158 hasPublicationYear "2003" @default.
• W2028160158 type Work @default.
• W2028160158 sameAs 2028160158 @default.
• W2028160158 citedByCount "79" @default.
• W2028160158 countsByYear W20281601582012 @default.
• W2028160158 countsByYear W20281601582013 @default.
• W2028160158 countsByYear W20281601582014 @default.
• W2028160158 countsByYear W20281601582015 @default.
• W2028160158 countsByYear W20281601582016 @default.
• W2028160158 countsByYear W20281601582017 @default.
• W2028160158 countsByYear W20281601582020 @default.
• W2028160158 countsByYear W20281601582021 @default.
• W2028160158 countsByYear W20281601582022 @default.
• W2028160158 crossrefType "journal-article" @default.
• W2028160158 hasAuthorship W2028160158A5004781738 @default.
• W2028160158 hasAuthorship W2028160158A5065658935 @default.
• W2028160158 hasAuthorship W2028160158A5073325557 @default.
• W2028160158 hasAuthorship W2028160158A5074077148 @default.
• W2028160158 hasBestOaLocation W20281601581 @default.
• W2028160158 hasConcept C126322002 @default.
• W2028160158 hasConcept C134018914 @default.
• W2028160158 hasConcept C153911025 @default.
• W2028160158 hasConcept C167734588 @default.
• W2028160158 hasConcept C170493617 @default.
• W2028160158 hasConcept C203014093 @default.
• W2028160158 hasConcept C2777025900 @default.
• W2028160158 hasConcept C2777292125 @default.
• W2028160158 hasConcept C2778271848 @default.
• W2028160158 hasConcept C2778886182 @default.
• W2028160158 hasConcept C2780394083 @default.
• W2028160158 hasConcept C502942594 @default.
• W2028160158 hasConcept C55493867 @default.
• W2028160158 hasConcept C71924100 @default.
• W2028160158 hasConcept C86803240 @default.
• W2028160158 hasConcept C89560881 @default.
• W2028160158 hasConcept C95444343 @default.
• W2028160158 hasConcept C97230052 @default.
• W2028160158 hasConceptScore W2028160158C126322002 @default.
• W2028160158 hasConceptScore W2028160158C134018914 @default.
• W2028160158 hasConceptScore W2028160158C153911025 @default.
• W2028160158 hasConceptScore W2028160158C167734588 @default.
• W2028160158 hasConceptScore W2028160158C170493617 @default.
• W2028160158 hasConceptScore W2028160158C203014093 @default.
• W2028160158 hasConceptScore W2028160158C2777025900 @default.
• W2028160158 hasConceptScore W2028160158C2777292125 @default.
• W2028160158 hasConceptScore W2028160158C2778271848 @default.
• W2028160158 hasConceptScore W2028160158C2778886182 @default.
• W2028160158 hasConceptScore W2028160158C2780394083 @default.
• W2028160158 hasConceptScore W2028160158C502942594 @default.
• W2028160158 hasConceptScore W2028160158C55493867 @default.
• W2028160158 hasConceptScore W2028160158C71924100 @default.
• W2028160158 hasConceptScore W2028160158C86803240 @default.
• W2028160158 hasConceptScore W2028160158C89560881 @default.
• W2028160158 hasConceptScore W2028160158C95444343 @default.
• W2028160158 hasConceptScore W2028160158C97230052 @default.
• W2028160158 hasIssue "10" @default.
• W2028160158 hasLocation W20281601581 @default.
• W2028160158 hasLocation W20281601582 @default.

• next